Lung cancer often shows lymph node metastasis in the pulmonary hilar or mediastinal regions during the early stage. Occasionally, the metastatic site is clinically found prior to the detection of the primary lesion of the lung. We present a rare case with primary-unknown small cell carcinoma appearing in the pulmonary hilar node. Immunohistochemical analysis was helpful in estimating the primary site . Since the first case of primary-unknown small cell carcinoma reported by Suemasu et al 1 was described, the number of such T0 lung cancer cases in Japan, as far as we know, is less than 10. 
INTRODUCTION
Lung cancer often shows lymph node metastasis in the pulmonary hilar or mediastinal regions during the early stage. Occasionally, the metastatic site is clinically found prior to the detection of the primary lesion of the lung. We present a rare case with primary-unknown small cell carcinoma appearing in the pulmonary hilar node. Immunohistochemical analysis was helpful in estimating the primary site . Since the first case of primary-unknown small cell carcinoma reported by Suemasu et al 1 was described, the number of such T0 lung cancer cases in Japan, as far as we know, is less than 10.
CASE
A 68-year-old man demonstrated an abnormal shadow in the right pulmonary hilar region on a chest X-ray examination during a routine medical checkup Figure 1 . He had smoked 40 cigarettes a day for 40 years, but his past medical history and physical examinations showed no abnormalities. The laboratory blood test profile was normal except for a slightly elevated neuron specific enolase NSE of 11 ng! ml normal range 10 ng! ml . A CT 
ABSTRACT
Background. Lung cancer rarely shows a lymph node metastasis to pulmonary hilar and! or mediastinal regions without the primary site of the lung being unable to be detected. Case. A 68-year-old man demonstrated a right abnormal hilar shadow on a chest X-ray film. A computed tomography CT revealed an enlarged mass at the right pulmonary hilar node, and this mass was diagnosed to be poorly differentiated carcinoma by transbronchial aspiration cytology. However, no primary lesion in the lung was apparent, and the extrathoracic findings showed no abnormalities despite a thorough examination. We thus performed a tumorectomy with right upper lobectomy and mediastinal nodal dissection because of the possibility of a lung origin based on the lymphatic routes to the tumor. The microscopical and immunohistochemical findings were consistent with small cell carcinoma in the pulmonary hilar node. Although no primary lesion of the resected lobe and also other lobes of the lung was found despite detailed examinations, positive immunoreactivity against anti-thyroid transcription factor-1 TTF-1 antibody revealed this tumor to have originated in the lung. Therefore, we consider that this patient is a rare case of primary unknown T0 lung cancer with metastasis in the pulmonary hilar lymph node. Conclusions. Second, primary carcinoma may arise from endogenous cells present within the affected pulmonary hilar or mediastinal lymph node. 4 In fact, gland inclusions from which epithelial tumor originates within the lymph node have been previously reported. 5 However, no evidence of this event has yet been confirmed. Therefore, further pathological study is required. The origin of this tumor may indeed be the lung tissue, because its morphologic and histologic aspects were compatible with a pulmonary origin, and the lymphatic drainage from the lung passes through these nodes. Furthermore, an immunohistochemical study may help determine the biological characteristics of the primary tumor, and its histological origin. We previously reported two cases of T0 lung cancer in which an immunohistochemical application of antibody against surfactant apoprotein on alveolar epithelial cells was a useful method for identifying a lung origin in metastatic adenocarcinoma to a lymph node. 6 In general, it is useful for the diagnosis of lung adenocarcinoma to apply an immunohistochemical method using cytokeratin 7 and 20 antibodies , 7, 8 and surfactant apoprotein antibody, whereas there are no expressions against these immunohistochemical antibodies in small cell lung cancer. Finally, in cases of unknown primary site of lung cancer, since the primary lesion may later be identified, a strict follow-up study after the operation is necessary 6 
